



Marksans Pharma Ltd.

NEWS RELEASE

8th February 2019, Mumbai - India

Marksans Pharma Limited has reported today its Financial Performance for the Q3 FY 2018-19 and for the Nine months period ended 31st December 2018

Performance Highlights- Consolidated (Nine Months)

- PAT at Rs.70.59 crores
- EBITDA at Rs.111.38 Crores
- EBITDA increase by 319 basis points
- Profit after Tax was Rs.70.59 crores for the period as compared to Rs.42.28 crores during previous period ,registering growth of **66.96%**
- EBITDA was Rs.111.38 crores for the period as compared to Rs.82.86 crores during previous period, registering growth of **34.42%**
- Consolidated EBITDA increased by **319** basis points from 11.61% to 14.80% during the period.
- Consolidated Revenue at Rs.**752.84** crores in Nine months of FY 2018-19 as compared to Rs.**713.73** crores during previous period, registering growth of **5.48%**.

Q3 FY 2018-19 – Consolidated

- Net Profit After Tax for the quarter was at Rs.25.13 Crores, as compared to Rs.17.46 crores during previous period ,registering growth of **43.93%**
- EBITDA for the quarter was at Rs.36.34 crores as compared to Rs.29.24 crores during previous period ,registering growth of **24.28%**
- Consolidated Revenue was at Rs.248.52 Crore as compared to Rs.218.82 crores during previous period ,registering growth of **13.57%**



CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com



Marksans Pharma Ltd.

Management Discussion and Analysis for the Nine months of FY 2018-19

Revenue Figures – Consolidated

INR in crores				
First Nine Months of FY 2018-19				
	FY 2018-19	FY 2017-18	Growth %	Mix %
Europe, UK – Formulations	323.14	328.23	-1.55%	42.92%
US & North America – Formulations	309.30	281.93	9.71%	41.09%
Australia & NZ – Formulations	79.40	74.95	5.94%	10.55%
Rest of World(ROW)	40.99	28.62	43.22%	5.44%
Consolidated Revenue from operations	752.84	713.73	5.48%	100.00%

Business Highlights

- Europe, UK Formulation business revenue was at Rs.323.14 crores as compared to Rs.328.23 crores achieved during previous year same period.
- US & North America Formulation business reported revenue of Rs.309.30 crores as against revenue of Rs.281.93 crores achieved during last year, registering growth of 9.71%.
- Australia & NZ Formulation business revenue was at Rs. 79.40 crores as compared Rs.74.95 crores achieved during previous year same period.
- Rest of World Formulation business was Rs.40.99 crores as compared to Rs.28.62 crores achieved during last year same period, registering growth of 43.22%.

About Marksans Pharma Limited

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including UK MHRA, US FDA & Australia TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterologicals and Anti-allergies. The company is marketing these products globally.



CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com



Marksans Pharma Ltd.

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Marksans may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Marksans Pharma Limited
11th Floor, "GRANDEUR", Veera desai Extension Road,
Oshiwara, Andheri – (West), Mumbai – 400 053, India
Tel:- +91 22 4001 2000, Fax:- +91 22 4001 2011.

